MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for multiple indications and therapeutic areas, including as a trigger for egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF), and other potential therapeutic areas.

More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical clinical trials.

MVT-602 is not approved by the FDA.

How it works

Kisspeptin is a naturally-occurring peptide that binds the KISS1 receptor and stimulates gonadotropin-releasing hormone (GnRH) release. Kisspeptin is required for puberty and maintenance of reproductive function, including follicular maturation and ovulation, the production of estrogen and progesterone in women, and the production of sperm and testosterone in men.

MVT-602, an oligopeptide kisspeptin-1 receptor agonist, has the potential to increase luteinizing hormone (LH), which stimulates egg maturation.

Clinical trial results

MVT-602 is not approved by the FDA.

In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen.

In June 2019, we presented data from a Phase 2a trial of MVT-602 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Results of this trial showed that the administration of MVT-602 produced an LH surge that approximated the natural mid-cycle LH surge and was associated with high rates of ovulation on ultrasound.

Adverse events in these studies were similar between placebo and the MVT-602 groups with no apparent dose-related effects.

Explore our pipeline

You are leaving, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.